INSIDER · CIK 2000389
Kastelein Johannes Jacob Pieter
Chief Scientific Officer, Director at NewAmsterdam Pharma Co N.V. (NAMS)
↗4 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$4.6MSold on the market
1Companies
Oct 2, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:30 | Sep 30, 2026 | NAMSNewAmsterdam Pharma Co N.V. | Chief Scientific Officer, Director | S · Sell10b5-1 | $25.03 | −50,246 | 69,302 | -42% | −$1.3M | ||
| Oct 2, 202616:30 | Sep 30, 2026 | NAMSNewAmsterdam Pharma Co N.V. | Chief Scientific Officer, Director | M · Exercise10b5-1 | — | +50,246 | 119,548 | +73% | — | ||
| Aug 25, 202616:30 | Aug 24, 2026 | NAMSNewAmsterdam Pharma Co N.V. | Chief Scientific Officer, Director | S · Sell10b5-1 | $26.91 | −125,000 | 69,302 | -64% | −$3.4M | ||
| Aug 25, 202616:30 | Aug 24, 2026 | NAMSNewAmsterdam Pharma Co N.V. | Chief Scientific Officer, Director | M · Exercise10b5-1 | — | +125,000 | 194,302 | +180% | — |